Comparison the Effect of Letrozole and Tomoxifin in infertile women with Clomid Citrate resistant in polycystic ovarian syndrome

Abstract

Polycystic ovary syndrome (PCOS) is the most frequent endocrine problem affect women in the reproductive age and commonest causes of hyperandrogenic anovulatory infertility. This study was aimed to evaluate the efficacy of letrozole on ovulation induction and pregnancy rate in comparison to tamoxifen in clomiphene CC-resistant PCOS patient. This prospective randomized study was included 80 patients divided into 2 equal groups, Group (1) involved 30 women who were given letrozole 2.5 mg tab orally once per day from day 5to 9 of the menstrual cycle, for 3 successive cycles. Group (2) included 30 women, had been received TMX with a dose of 20 mg per day starting from day 5 of manse to day 9 of it, for 3 successive cycles, compare the effectiveness of letrozole and tamoxifen in management of clomiphene citrate resistance PCOS patients, during of 15th August 2015 to 15th of December 2016 and was performed infertility clinics of AL-Batool teaching hospital. The results of this study revealed that Letrozole is better than tamoxifen in producing acceptable follicular diameter, endometrial thickness and pregnancy rate in women with the clomiphene-resistant polycystic ovarian syndrome. With pregnancy rate of (12%) in tamoxifen group versus (27%) in letrozole group. Letrozole is effective, an available drug that is superior to tamoxifen as ovulation induction agent in clomiphene-resistant polycystic ovarian syndrome.